https://scholars.lib.ntu.edu.tw/handle/123456789/475437
標題: | Bosentan is an alternative treatment option in a child with severe idiopathic pulmonary artery hypertension and abnormal liver enzymes | 作者: | HSAO-HSUN HSU EN-TING WU JIN-SHING CHEN MEI-HWAN WU JOU-KOU WANG Ko W.-J. SHU-CHIEN HUANG Lee Y.-C. |
公開日期: | 2005 | 卷: | 1 | 期: | 4 | 起(迄)頁: | 140-143 | 來源出版物: | Respiratory Medicine Extra | 摘要: | The standard treatment for children with idiopathic pulmonary artery hypertension (IPAH) is epoprostenol. Few reports have evaluated oral bosentan therapy in children with severe IPAH. This report details the use of bosentan in a 16-month-old child with severe IPAH who presented as New York Heart Association (NYHA) functional class (FC) IV. His general condition, NYHA FC, serum aminotransferase levels, and arterial blood gases improved after 6 months of treatment. This case provides an example where twofold aminotransferase elevations suspected to result from right heart failure might not be a contraindication for bosentan therapy in children with IPAH. ? 2005 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646074075&doi=10.1016%2fj.rmedx.2005.08.004&partnerID=40&md5=b9cdaca3686f51aeb8c6c9fe0bed8cc1 https://scholars.lib.ntu.edu.tw/handle/123456789/475437 |
ISSN: | 1744-9049 | DOI: | 10.1016/j.rmedx.2005.08.004 | SDG/關鍵字: | aminotransferase; bosentan; liver enzyme; absence of side effects; aminotransferase blood level; article; case report; clinical feature; disease classification; disease severity; evaluation; heart right ventricle failure; human; liver toxicity; male; preschool child; priority journal; pulmonary hypertension; treatment outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。